gpt-dict.com

副乾酪乳桿菌 K71/LP33 Lactobacillus paracasei (K71 / LP33) × 幽門螺旋桿菌

結論：證據支持但有警示

L.

C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 💊 檢驗 / 藥物交互作用

L. paracasei 對幽門螺旋桿菌的證據存在嚴重的「菌株錯配」問題：PubMed 最佳菌株特異性 RCT 為 L. paracasei HP7（韓國 Yoon 2019）配合甘草萃取的小規模試驗，而非台灣市場主流的 LP33／K71 株；2024 Lactobacillus spp. 屬層級 meta-analysis 雖支持作為三合一療法輔助，但未拆分至 paracasei。

Mayo／Cleveland／Harvard 三大 L5 共識來源均無此配對之專文，ACG 2024 與 Maastricht VI 僅以「probiotics 一般可考慮減少副作用」籠統帶過，未具名 LP33。

台灣 TFDA 健字號核可範圍為「免疫調節／輔助調整過敏體質」，並非 H. pylori 根除適應症。

整體屬「初步證據存在但菌株特異性、權威背書、規格化劑量皆不足」之 C 級。

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.63
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
72%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）

各層「支持此療效」的程度

分數越低＝該層越不支持
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L5 臨床機構權威立場
0.55
L3 機轉生理合理性
0.65
L2 PubMed原始文獻
0.75
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.625
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

A Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication
PMID: 41327607 2025 統合分析 n = 2,054
結論：Adding Lactobacillus modestly increased the eradication rate (RR 1.04, 95% CI 1.01-1.07; p=0.009, high-certainty), but pooled multiple strains so no paracasei-specific effect could be isolated.
🟢 高品質 效應量：RR 1.04 (95% CI 1.01-1.07), p=0.009
前往 PubMed
Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication
PMID: 39722187 2024 統合分析
結論：Across 26 studies Lactobacillus spp. as an adjunct significantly improved eradication (per-protocol RR 1.063, p<0.001) and reduced side effects, but reported no L. paracasei subgroup and the wide/heterogeneous CIs limit precision.
效應量：RR 1.063, p<0.001 (per-protocol)
前往 PubMed
Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis
PMID: 37256113 2023 統合分析 n = 9,004
結論：Across 34 RCTs (9,004 patients) Bifidobacterium-Lactobacillus and Bifidobacterium-Lactobacillus-Saccharomyces combinations ranked best (eradication 78.3% and 88.2%); L. paracasei was not separately identified as a top performer.
政府資助 效應量：Best combos eradication 78.3-88.2% (no paracasei-specific OR reported)
前往 PubMed
Fermented milk containing Lactobacillus paracasei and Glycyrrhiza glabra has a beneficial effect in patients with Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study
PMID: 31464895 2019 RCT (double-blind) n = 142
結論：Fermented milk with L. paracasei HP7 plus licorice reduced 13C-UBT density (20.8% to 16.9%, p=0.035) and improved histologic inflammation, while placebo did not (p=0.130); it lowered bacterial load but did not demonstrate eradication.
效應量：13C-UBT 20.8±13.2% to 16.9±10.8%, p=0.035
前往 PubMed
A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy
PMID: 34579049 2021 RCT (double-blind) n = 136
結論：The LP33-containing (CNCM I-1518) multi-strain product showed NO effect on antibiotic-associated diarrhea or GI symptoms; only secondary microbiota-recovery markers improved (beta-diversity p=0.02), with no eradication benefit shown.
⚠️ 廠商資助 效應量：Null on AAD/GI symptoms; microbiota beta-diversity p=0.02 (secondary)
前往 PubMed
Anti-Helicobacter pylori activity of a complex mixture of Lactobacillus paracasei HP7 including the extract of Perilla frutescens var. acuta and Glycyrrhiza glabra
PMID: 33134159 2020 Cohort
結論：In an animal/in-vitro model the L. paracasei HP7 mixture reduced H. pylori infection rate and gastric inflammation (lower serum IL-8); preclinical only, no human clinical endpoint.
🟠 品質有限 效應量：Reduced infection rate and IL-8 (preclinical, no clinical effect size)
前往 PubMed

L4a US FDA
未表態
— 本適應症無對應資料
L4b EU EFSA
反對
— 本適應症無對應資料
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
— 本適應症無對應資料
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made. 來源↗
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
中性
— 本適應症無對應資料
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
Interventions/Exposure: Proton pump inhibitor (PPI)-clarithromycin triple therapy, bismuth quadruple therapy (BQT), concomitant therapy, rifabutin-triple therapy, potassium-competitive acid blocker (PCAB) dual therapy, PCAB triple therapy, quinolone-based therapy, high-dose PPI dual therapy, susceptibility-guided therapy, and probiotics. 來源↗

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽

台灣 PTT / Dcard / Mobile01 上 LP33 的討論幾乎全部集中於過敏（鼻過敏、塵蟎、異位性皮膚炎）與一般腸胃保健，僅少數網友順帶提到「胃比較舒服」，並未見到專門針對幽門螺旋桿菌的使用心得；社群普遍把幽門桿菌的益生菌話題指向 Lactobacillus reuteri DSM17648 或雷特氏 B 菌，而非 LP33。

💬社群實感

資料不足

破解迷思 社群最常見的 4 個誤解
✓
事實誤以為 LP33 可以「殺死」或「根除」幽門螺旋桿菌，事實上 LP33 為過敏與免疫調節雙效認證，並無除菌健康食品認證
✓
事實把 LP33 與雷特氏 B 菌（Bifidobacterium lactis）或 Lactobacillus reuteri DSM17648 混淆，後二者才是社群常見「以菌制菌」的對象
✓
事實認為喝 LP33 優酪乳就能取代抗生素三合一療法
✓
事實以為所有副乾酪乳桿菌（L. paracasei）菌株效果相同，忽略 LP33 是特定菌株且菌數標示為 5 億 CFU/顆
🩹 社群通報的副作用
  • 初期腹瀉、軟便（前 1–2 週）
  • 長青春痘 / 皮膚冒疹的調整反應
  • 脹氣、排氣增加
  • 部分人反映無感
🏷️ 社群熱議品牌

依論壇被提及頻率，非銷售或品質排序。

  • 統一 LP33 益生菌膠囊
  • 統一 LP33 機能優酪乳
  • 統一 AB 優酪乳
  • 義美 LP33 優酪乳
  • 福樂 LP33

⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

LP33 過敏靈 健字號

代表來源 ↗
L10b · TFDA 法定身份 官方認定

本產品經衛生福利部認證，具有輔助調整過敏體質之保健功效

來源 ↗

  • 四合一療法 (bismuth quadruple)
  • 三合一療法 (clarithromycin triple, 低抗藥區)
✓ PMID 可查證引用皆附 NCBI PubMed 原始連結
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-09 claim_version: v11 engine_version: v1.0 claim_id: CLM-COND-helicobacter-pylori-INT-lactobacillus-paracasei-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-helicobacter-pylori-INT-lactobacillus-paracasei-001/",
  "datePublished": "2026-06-09",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "副乾酪乳桿菌 K71/LP33能改善幽門螺旋桿菌",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}